Chinese Medicine Shenqibufei Attenuates Chronic Obstructive Pulmonary Disease

Kui Zhang,Guiying Wu,Xiangyan Zhang,Ping Yang,Zhu Yang
2017-01-01
Abstract:Objective: To evaluate the therapeutic effect of Chinese medicine ShenqiBufei (SBF) onchronic obstructive pulmonary disease (COPD) in a rat COPD model. Methods: SBF was prepared from Astragalus, Codonopsis, Psoraleae, Salviae, Stemonae, Cortex Mori and Radix asteris. The effect of SBF on cigarette smoke extract (CSE)-induced growth of rat airway smooth muscle cells (AMSC), histone deacetylase 2 (HDAC2) and nuclear factor kappa B (NF-kappa B) p65 protein expression were determined by MTT assay and Western blot. Preclinical COPD model was induced by cigarette-smoke exposure for 28 days plus lipopolysaccharide intratracheal instillation on day 1 and day 14 (CSL) in Sprague-Dawley male rats. The rats either received SBF (35.2 g/kg body weight per day for 28 days) or without SBF treatment. Rats in sham group received only PBS without CSL and SBF treatment. Rat respiratory parameters such as respiratory rate, FEV0.3/FVC, resistance inspiration (Ri), resistance expiration (Re) were measured on day 28 before sacrifice. Results: SBF treatment significantly suppressed CSE-induced proliferation of ASMC, inhibited NF-kappa Bp65 but enhanced HDAC2 expression in ASMC in vitro. In vivo, SBF treatment significantly suppressed the thickening of small pulmonary airway wall, inhibited NF-kappa Bp65 but promoted HDAC2 protein expression in small airway wall, and improved lung function in rat COPD model. Conclusions: The Chinese medicine SBF provides a new approach for the treatment of COPD.
What problem does this paper attempt to address?